BioReference Laboratories Inc., the Elmwood Park-based health company, has acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche, it announced this week.
The acquisition, which includes Ariosa’s noninvasive prenatal screening test, the Harmony Prenatal Test, will complement BioReference’s current offerings, which include the ClariTest Core — which uses the same core technology as the Harmony test.
“Throughout BioReference’s 40-year legacy of diagnostic testing, women’s health has been at the forefront of our focus,” Dr. Jon R. Cohen, executive chairman, said in a prepared statement. “Last year, there were about 6 million pregnancies in the U.S., and prenatal screening for Down syndrome has become common practice. Acquiring the U.S. Ariosa centralized laboratory prenatal testing business allows us to expand our NIPS offerings and further underscores our commitment to prenatal screening.”
